Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 247.98B |
| Revenue (ttm) | 44.94B |
| Net Income (ttm) | 11.09B |
| Shares Out | 1.91B |
| EPS (ttm) | 5.67 |
| PE Ratio | 22.92 |
| Forward PE | 18.36 |
| Dividend | 3.70 (2.85%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 3,957,072 |
| Average Volume | 3,792,498 |
| Open | 129.10 |
| Previous Close | 129.96 |
| Day's Range | 126.06 - 129.10 |
| 52-Week Range | 81.10 - 131.00 |
| Beta | 0.46 |
| RSI | 58.16 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Commit fully to the role you’re in now, and your career may thank you later: Novartis CEO Vas Narasimhan
Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan reflects on the unlikely decisions that took him from the “steel town” of Pittsburgh...
What's Driving the Market Sentiment Around Novartis AG?
Novartis AG's (NYSE: NVS) short interest as a percent of float has risen 44.44% since its last report. According to exchange reported data, there are now 7.49 million shares sold short , which is 0.3...
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells. ... Full story available on Benzinga.com
Henrietta Lacks: Family of woman whose cells were 'stolen' settles second lawsuit
Novartis is the second drug company to settle a lawsuit brought by the family of a woman whose cells have enabled huge advances in science.
Novartis (NVS) Expands with New Facilities and Job Creation
Novartis (NVS) Expands with New Facilities and Job Creation
The immortal life of Henrietta Lacks lawsuits gets a bit shorter with Novartis settlement
Details of the agreement, which was finalized in federal court in Maryland this month, aren't public.
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Completes Acquisition of Avidity Biosciences
Novartis (NVS) Completes Acquisition of Avidity Biosciences
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-bill...
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ma...
Novartis, Genentech file suit alleging illegal importation of prescription drug
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and...
Novartis picks Texas to build next radioligand therapy site
Novartis to build radioligand therapy site in Texas to expand US manufacturing
Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwi...
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
It has the qualities of a buy-and-forget stock.
Novartis: Pluvicto Shows Effectiveness In Real-world Studies
(RTTNews) - Novartis (NVS) said multiple US real-world studies reinforced earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer. Real-world use of Pluvicto res...
Novartis (NVS) Showcases New Rhapsido Data at AAAAI Meeting
Novartis (NVS) Showcases New Rhapsido Data at AAAAI Meeting
Novartis Presents 5 Key Abstracts Evaluating Rhapsido In CSU, Peanut Allergy At AAAAI Annual Meet
(RTTNews) - Novartis AG (NVS) Monday said that it will present data from five key abstracts evaluating Rhapsido, also known as Remibrutinib in chronic spontaneous urticaria or CSU and as an investigat...
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontan...
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.
Novartis to exit listed Indian arm in Rs 1,446cr deal
India Business News: New Delhi: Swiss drug firm Novartis will sell its entire stake of nearly 71% in its listed Indian subsidiary for about Rs 1,446 crore to a clutch of p.
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees